1. Home
  2. CBIO vs ERC Comparison

CBIO vs ERC Comparison

Compare CBIO & ERC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • ERC
  • Stock Information
  • Founded
  • CBIO 2003
  • ERC 2003
  • Country
  • CBIO United States
  • ERC United States
  • Employees
  • CBIO N/A
  • ERC N/A
  • Industry
  • CBIO
  • ERC Finance/Investors Services
  • Sector
  • CBIO
  • ERC Finance
  • Exchange
  • CBIO Nasdaq
  • ERC Nasdaq
  • Market Cap
  • CBIO 308.0M
  • ERC 263.4M
  • IPO Year
  • CBIO N/A
  • ERC N/A
  • Fundamental
  • Price
  • CBIO $12.85
  • ERC $9.46
  • Analyst Decision
  • CBIO Strong Buy
  • ERC
  • Analyst Count
  • CBIO 3
  • ERC 0
  • Target Price
  • CBIO $25.67
  • ERC N/A
  • AVG Volume (30 Days)
  • CBIO 108.6K
  • ERC 64.4K
  • Earning Date
  • CBIO 07-31-2025
  • ERC 01-01-0001
  • Dividend Yield
  • CBIO N/A
  • ERC 8.37%
  • EPS Growth
  • CBIO N/A
  • ERC N/A
  • EPS
  • CBIO N/A
  • ERC 0.72
  • Revenue
  • CBIO N/A
  • ERC N/A
  • Revenue This Year
  • CBIO N/A
  • ERC N/A
  • Revenue Next Year
  • CBIO N/A
  • ERC N/A
  • P/E Ratio
  • CBIO N/A
  • ERC $12.92
  • Revenue Growth
  • CBIO N/A
  • ERC N/A
  • 52 Week Low
  • CBIO $10.90
  • ERC $8.51
  • 52 Week High
  • CBIO $21.40
  • ERC $9.74
  • Technical
  • Relative Strength Index (RSI)
  • CBIO N/A
  • ERC 57.05
  • Support Level
  • CBIO N/A
  • ERC $9.30
  • Resistance Level
  • CBIO N/A
  • ERC $9.48
  • Average True Range (ATR)
  • CBIO 0.00
  • ERC 0.06
  • MACD
  • CBIO 0.00
  • ERC 0.01
  • Stochastic Oscillator
  • CBIO 0.00
  • ERC 87.22

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About ERC Allspring Multi-Sector Income Fund

Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.

Share on Social Networks: